ALNY Q3 2017 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$42B

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M+25.2% YoY

Gross Profit

$17M100.0% margin

Operating Income

-$126M-735.8% margin

Net Income

-$123M-719.1% margin

EPS (Diluted)

$-1.34

QoQ Revenue Growth

+7.3%

Cash Flow

Operating Cash Flow

-$98M

Free Cash Flow

-$124M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$299M

Stockholders' Equity

$1.1B

Cash & Equivalents

$202M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$14M	+25.2%
Gross Profit	$17M	$14M	+25.2%
Operating Income	-$126M	-$107M	-17.9%
Net Income	-$123M	-$104M	-18.1%